Bristol Myers SquibbBMY
NYSE · USA · Segment 2 of 8 in the Medicine, pharma & life science value chain: Big pharma
American pharmaceutical group with strengths in oncology (Opdivo) and immunology, plus a neuroscience pipeline.
Big pharma: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Key metrics
Market cap
$117B
Price
$57.51
Today
−0.7%
Return YTD
+7.4%
Return 1Y
+21.6%
P/E
19.6
P/S
2.4
P/B
5.8
Data as of 2026-07-10 · updates daily after U.S. close
Theme exposure
In the value chain
Products & services
- Oncology (Opdivo)
- Immunology
- Hematology
Competitors
- Merck
- Pfizer
- AstraZeneca
Risks
- Patent cliff (Eliquis, Opdivo)
- Pipeline transition
Same segment: Big pharma
See where Bristol Myers Squibb sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →